TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03912077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioural Therapy
Description: 7-session psychosocial intervention
Study: NCT00028990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
Study: NCT00679497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-B
Description: * Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -3 immunisations at week 0, 4 and 16
Study: NCT02085434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITLINE practice-based referral program
Description: The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
Study: NCT04547205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK109
Description: AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
Study: NCT01596998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine without epinephrine
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determining the extent of the block
Description: The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
Study: NCT03759535

Intervention type: DIAGNOSTIC_TEST
Intervention: Acute rejection
Description: Donor derived cell free DNA
Study: NCT00921700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Paracetamol
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Paracetamol + Codeine
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol + Codeine
Description: Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of lactose as placebo in gelatine capsules
Study: NCT03726164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Conditioning
Description: A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham protocol
Description: An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
Study: NCT00836212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reducing dose of Lopinavir
Description: Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reducing dose of efavirenz
Description: Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
Study: NCT01791192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Fingolimod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Corticosteroid
Description: Oral Corticosteroid
Study: NCT02519166

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing
Study: NCT04421495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: the eligible patients will be give damanid-containing regimen
Study: NCT04159038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will continue usual WIC care.
Study: NCT01141595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Study: NCT03150225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent training
Description: In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent training
Description: In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eurycoma longifolia
Description: Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eurycoma longifolia
Description: Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
Study: NCT02689830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bead Block
Description: Prostate embolization
Study: NCT00516737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rizatriptan benzoate
Description: Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo; one dose, treatment of a single migraine attack
Study: NCT03911765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital cognitive training
Description: Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: digital cognitive training
Description: Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
Study: NCT00870753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 90 min hatha yoga 2 times per week for 12 weeks.
Study: NCT01357369

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
Study: NCT02122978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: MBCT 8 week course delivered by trained facilitator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSC - minimal contact
Description: 8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Self Compassion Therapy
Description: Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
Study: NCT03790280

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HFO analysis
Description: We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
Study: NCT01049763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
Study: NCT01446419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept Treatment
Description: Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
Study: NCT01767883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Clinical Decision Support
Description: The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation~* Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Only
Description: * CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms
Study: NCT00915343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone (modified release), oral tablet 20 and 5 mg
Description: The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, oral tablet, 10 mg
Description: The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
Study: NCT02349698

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Chimeric Antigen Receptor Modified T cells Targeting CD19
Description: T cells modified with CD19 targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Chimeric Antigen Receptor Modified T cells Targeting CD19
Description: T cells modified with CD19 targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Chimeric Antigen Receptor Modified T cells Targeting CD19
Description: T cells modified with CD19 targeted chimeric antigen receptor.
Study: NCT03286855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebuliser
Description: The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hospital Care
Description: The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser.
Study: NCT03186235

Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood

Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood

Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood

Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood

Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood
Study: NCT01233778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: 60g Canola oil daily per 3000kcal diet provided in a supplemental shake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid + DHA Canola Oil
Description: 60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid Canola Oil
Description: 60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax Oil
Description: 36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safflower Oil
Description: 45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
Study: NCT01928160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04884555

Intervention type: OTHER
Intervention: Standard neurorehabilitation
Description: Routine post-stroke rehabilitation

Intervention type: DIAGNOSTIC_TEST
Intervention: Thiol-Disulphide Homeostasis
Description: Monitoring the levels of thiol and disulphide in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Thiol-Disulphide Homeostasis
Description: Monitoring the levels of thiol and disulphide in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidized-reduced Glutathione Homeostasis
Description: Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidized-reduced Glutathione Homeostasis
Description: Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
Study: NCT00987363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of autologous bone marrow cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of autologous bone marrow cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of autologous bone marrow cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
Study: NCT01708460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT02849366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT04442841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: It may be GSk or MSD vaccine
Study: NCT03721926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Oncology Collaborative Care
Description: Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
Study: NCT00679705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritodrine
Description: Ritodrine (Pre-Par), maximum 400 µg/minute, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Atosiban (Tractocile), maximum 300 µg/minute, IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose 5%, IV
Study: NCT02847130

Intervention type: OTHER
Intervention: Informational Intervention
Description: Participate in focus group

Intervention type: OTHER
Intervention: Interview
Description: Undergo one-on-one interviews

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies